Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.